SMN2 copy number appears to be the most important predictor of the clinical phenotype in individuals with spinal muscular atrophy.
Why this matters
Greater understanding of genetic variants that underlie clinical heterogeneity in spinal muscular atrophy is urgently required to improve neonatal screening programs and therapeutic strategies. The observation that gene copies of SMN2 are structurally different both between and within individuals could have important consequences for current counselling and treatment practices.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.